A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07404553

Enrollment

126

Registered

2026-02-11

Start date

2026-04-30

Completion date

2028-08-01

Last updated

2026-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Brief summary

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.

Interventions

DRUGSHR-1918 Injection

SHR-1918 injection.

DRUGSHR-1918 Injection Placebo

SHR-1918 injection placebo.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. Male and female ≥ 18 years old and ≤ 85 years old, who is able and willing to provide a written informed consent. 2. TG ≤ 5.6 mmol/L. 3. LDL-C ≥ 2.6 mmol/L for moderate to high ASCVD risk, LDL-C ≥ 1.8 mmol/L for very high ASCVD risk, LDL-C ≥ 1.4 mmol/L for ultra-high ASCVD risk. 4. Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and after the last dose, and agree to use contraceptive methods as specified in the protocol.

Exclusion criteria

1. History of severe allergies/hypersensitivity reactions, or clinically significant allergies/hypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures. 2. Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization. 3. Acute ischemic ASCVD events within 3 months prior to screening or randomization. 4. Have severe cardiac arrhythmia within 3 months prior to screening or randomization. 5. Echocardiography indicates a left ventricular ejection fraction (LVEF) of less than 30% within 3 months prior to screening. 6. History of percutaneous coronary intervention, history of coronary artery bypass grafting (CABG), history of peripheral arterial revascularisation within 1 month prior to screening or randomization. 7. Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension. 8. Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization. 9. Malignant tumors within 5 years. 10. It's planned to research transcutaneous coronary intervention, coronary artery bypass grafting, carotid or peripheral artery reconstruction, pacemaker implantation, cardiac resynchronisation therapy (CRT), implantable cardioverter defibrillator (ICD) implantation and other implantations during the study. 11. Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening. 12. Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period. 13. History of drug use, substance abuse, and alcohol abuse. 14. Participated in or is participating in other clinical studies and has received study interventions within the past month prior to screening. 15. Researchers determine that the subject has poor compliance or any factors that make them unsuitable for participation in this trial, including but not limited to participation in the study placing the subject at unacceptable risk or potentially interfering with the study results.

Design outcomes

Primary

Measure	Time frame	Description
Percentage change in low density lipoprotein cholesterol (LDL-C) levels at Week 12 relative to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in low density lipoprotein cholesterol (LDL-C) levels at Week 24 relative to baseline.	At 24 weeks of treatment.	Phase 3.

Secondary

Measure	Time frame	Description
Percentage change in non-high-density lipoprotein cholesterol (non-HDL-C) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in triglyceride (TG) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in total cholesterol (TC) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in apolipoprotein B (ApoB) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in Apolipoprotein A1 (ApoA1) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Change in triglyceride (TG) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Change in non-high-density lipoprotein cholesterol (non-HDL-C) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Change in total cholesterol (TC) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Change in apolipoprotein B (ApoB) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Change in Apolipoprotein A1 (ApoA1) relative to baseline.	AT 12 weeks of treatment.	Phase 2.
Change in Lipoprotein(a) (Lp(a)) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in Lipoprotein(a) (Lp(a)) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Change in high-density lipoprotein cholesterol (HDL-C) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in high-density lipoprotein cholesterol (HDL-C) relative to baseline.	At 12 weeks of treatment.	Phase 2.
Proportion of subjects with the overall LDL-C achievement rate.	At 12 weeks of treatment.	Phase 2.
Proportion of subjects with the LDL-C achievement rates in different risk groups.	At 12 weeks of treatment.	Phase 2.
Change in LDL-C decreased by ≥ 50% to baseline.	At 12 weeks of treatment.	Phase 2.
Percentage change in LDL-C decreased by ≥ 50% to baseline.	At 12 weeks of treatment.	Phase 2.
Incidence and severity of adverse events (AEs).	Approximately 12 weeks.	Phase 2.
Incidence and severity of injection site reactions.	Approximately 12 weeks.	Phase 2.
Percentage change in non-HDL-C relative to baseline.	At 24 weeks of treatment.	Phase 3.
Percentage change in TG relative to baseline.	At 24 weeks of treatment.	Phase 3.
Percentage change in TC relative to baseline.	At 24 weeks of treatment.	Phase 3.
Percentage change in ApoB relative to baseline.	At 24 weeks of treatment.	Phase 3.
Percentage change in ApoA1 relative to baseline.	At 24 weeks of treatment.	Phase 3.
Change in TG relative to baseline.	At 24 weeks of treatment.	Phase 3.
Change in non-HDL-C relative to baseline.	At 24 weeks of treatment.	Phase 3.
Change in TC relative to baseline.	At 24 weeks of treatment.	Phase 3.
Change in ApoB relative to baseline.	At 24 weeks of treatment.	Phase 3.
Change in ApoA1 relative to baseline.	At 24 weeks of treatment.	Phase 3.
Change in Lp(a) relative to baseline.	At 24 weeks of treatment.	Phase 3.
Percentage change in Lp(a) relative to baseline.	At 24 weeks of treatment.	Phase 3.
Change in HDL-C relative to baseline.	At 24 weeks of treatment.	Phase 3.
Percentage change in HDL-C relative to baseline.	At 24 weeks of treatment.	Phase 3.

Countries

China

Contacts

CONTACTMiaomiao Shi

miaomiao.shi@hengrui.com+86-0518-82342973

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 17, 2026